DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for monocytic leukemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMonocytic leukemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for monocytic leukemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ASXL transcriptional regulator 1 (ASXL1) — ASXL1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8SVF · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Monocytic leukemia is described in a 1947 case report as a disease with an erratic course, where momentary observations can lead to erroneous conclusions. The report emphasises studying the natural history of the disease to reconcile conflicting opinions about its origin and characteristics. A 1967 clinical appraisal of chronic monocytic leukemia notes that some authors question its existence as a distinct entity. Among 25 patients at Johns Hopkins Hospital since 1955, the syndrome was mainly characterised by a long preleukemic phase with proliferative dysfunction of various blood elements, often presenting as refractory anemia up to 16 years before monocytes were numerous enough for diagnosis.
A 1978 report describes two adolescents whose early detection and treatment of acute monocytic leukemia was hampered by positive slide tests for infectious mononucleosis. The authors note this is important given the development of specific therapy effective for certain subtypes of nonlymphocytic leukemia at that time. A 1988 study using a human acute monocytic leukemia cell line (THP-1) found that its culture medium could induce normal human monocytes to spread, an ability not found in culture medium from a promyelocytic leukemia cell line (HL-60) or a diploid human fibroblast cell line. The monocyte spreading activity was found in a fraction with a molecular weight of about 70,000, which also increased production of angiotensin converting enzyme and Fc receptor sites for IgG on normal human monocytes.
No clinical trial data for any drug treatment of monocytic leukemia is provided in these abstracts. The 1947 paper explicitly warns against drawing conclusions from inconstant observations. The 1967 paper describes a syndrome whose very existence is questioned. What is missing is any controlled trial of a specific therapy, any modern molecular stratification of patients, and any funding for prospective studies that could move beyond case reports and cell-line experiments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Blood · 1947 · 18 citations · open access
MONOCYTIC LEUKEMIA A CASE REPORT ILLUSTRATING VARIATIONS IN THE CLINICAL PICTURE
AbstractAbstract Monocytic leukemia is an entity that has engendered a variety of divergent clinical and histologic opinions. A case is presented in which prolonged and intensive clinical and laboratory observations demonstrate the erratic course of this disease and illustrate the erroneous conclusions that may be derived from inconstant, momentary observations of this dynamic process. Study of the "natural history" of monocytic leukemia yields observations which tend to reconcile many of the hitherto conflicting opinions regarding this disease. The origin and characteristics of the monocytic cell are discussed, and its probable derivation from mesenchyma is emphasized.
AbstractThe citation of rare cases is of value only so far as it makes for more exact diagnosis, which in turn tends to make the treatment of disease less empirical. The purpose of this paper is to report a case in which there were a blood picture of monocytic leukemia and pathologic involvement of the reticulo-endothelial system. For this clinical picture the title of monocytic chloroma is suggested. A brief review of the literature on chloroma, monocytic leukemia and the reticulo-endothelial system is also presented. REPORT OF CASES History. —F. C., a white American laborer 55 years of age, was brought to the Eye Clinic of the University Hospital on Nov. 26, 1934. He complained of protrusion of the left eye associated with swelling of the lids, diminution of visual acuity, a feeling of fatigue in both eyes and a bulging red mass at the inner angle of the left
Medical and Pediatric Oncology · 1978 · 7 citations
Positive monospot tests preceding the diagnosis of acute monocytic leukemia in two adolescents
AbstractThe early detection and treatment of two cases of acute monocytic leukemia (AMoL) was hampered by the presence of positive slide tests for infectious mononucleosis (IM). This assumes great importance with the recent development of specific therapy, effective for certain subtypes of nonlymphocytic leukemia.
Monocyte Activating Factor Originally Found in Sarcoidosis Sera
AbstractAbstract The culture medium of a human acute monocytic leukemia cell line (THP‐1) was able to induce normal human monocytes to spread. No such ability was found either in the culture medium of a promyelocytic leukemia cell line (HL‐60) nor in that of a diploid human fibroblast cell line (Flow 7000). Gel filtration of the culture medium of THP‐1 cells on a size exclusion column (TSKgel G3000SW) revealed that the most obvious monocyte spreading activity was found in the fraction eluted at the position with a molecular weight of about 70,000. This fraction was also able to increase production of angiotensin converting enzyme and Fc receptor sites for IgG on normal human monocytes.
Abstracts1 May 1967Chronic Monocytic Leukemia: A Clinical Appraisal.Bruce L. Evatt, M.D., Allen M. Mondzac, M.D., J. Richard Gaintner, M.D.Bruce L. Evatt, M.D.Search for more papers by this author, Allen M. Mondzac, M.D.Search for more papers by this author, J. Richard Gaintner, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-5-1041_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough acute monocytic leukemia is a relatively well-defined clinical entity, the chronic form of monocytic leukemia has been given little attention. Some authors even question its existence. Since 1955 there have been 25 patients at the Johns Hopkins Hospital with a syndrome that is appropriately designated "chronic monocytic leukemia." These cases were mainly characterized by a long preleukemic phase with proliferative dysfunction of various blood elements, even before monocytes were present in sufficient numbers to make the diagnosis. The most common blood abnormality was that of refractory anemia and was present as long as 16 years before the onset of... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Baltimore, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1967Volume 66, Issue 5Page: 1041-1042KeywordsAcute monocytic leukemiaAnemiaBloodMonocytes Issue Published: 1 May 1967 PDF DownloadLoading ...
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
